Publications by authors named "Vladimir Y Melnichenko"
High-dose immunosuppressive therapy (HDIT) with autologous hematopoietic stem cell transplantation (AHSCT) is a promising approach to treatment of multiple sclerosis (MS) patients. In this paper, we present the long-term outcomes of a prospective single-center study with the analysis of the safety and efficacy of HDIT + AHSCT with reduced-intensity BEAM-like conditioning regimen in 99 MS patients: mean age-35 years old; male/female-39/60; median Expanded Disability Status Scale (EDSS) = 3.5; 43 relapsing/remitting MS, 56 progressive MS.
View Article and Find Full Text PDFHigh-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation (AHSCT) is a new and promising approach to multiple sclerosis (MS) treatment. In this article, we present the results of a prospective phase II open-label single-center study with the analysis of the safety and efficacy of high-dose immunosuppressive therapy+AHSCT with reduced-intensity conditioning regimen in 95 patients with different types of MS. The patients underwent early, conventional, and salvage/late transplantation.
View Article and Find Full Text PDFArticle Synopsis
- High-dose immunosuppressive therapy (HDIT) with autologous hematopoietic stem cell transplantation (auto-HSCT) is a new way to help people with multiple sclerosis (MS) because there aren’t many good treatments available.
- A study with 50 MS patients showed that no one died from the treatment and most people handled it well.
- After the treatment, 28 patients felt better, while 17 patients had their condition stay the same, showing that HDIT + auto-HSCT could be good for treating MS in different ways.